Targeting the mitogen-activated protein kinase cascade to treat cancer

Nature Reviews Cancer

Volumn 4, Issue 12, 2004, Pages 937-947

  Sebolt Leopold, Judith S ^a   Herrera, Roman ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ARRY 142886; AZD 3409; BEVACIZUMAB; L 778123; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; SORAFENIB; SUNITINIB; TIPIFARNIB; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; PROTEIN TARGETING; RASH; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY;

CELL CYCLE; CELL DIVISION; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; NEOPLASMS; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

EID: 10344258041     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1503     Document Type: Review

References (110)

1. Hahn, W. C. & Weinberg, R. A. Modelling the molecular circuitry of cancer. Nature Rev. Cancer 411, 331-341 (2002).
2. Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348 (2001).
3. Grossmann, J. Molecular mechanisms of 'detachment-induced apoptosis - anoikis'. Apoptosis 7, 247-260 (2002).
4. Nelson, W. J. & Nusse, R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 303, 1483-1487 (2004).
5. Assoian, R. K. Anchorage-dependent cell cycle progression. J. Cell Biol. 136, 1-4 (1997).
6. Roovers, K. & Assoian, R. K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22, 818-826 (2000).
7. MAPK (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol. Endocrinol. 6, 845-854 (1992).
8. MAPK are required for fibroblast proliferation. Proc. Natl Acad. Sci. USA 90, 8319-8323 (1993).
9. Dudley, D.T., Pang, L, Decker, S.J., Bridges, A.J. & Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl Acad. Sci. USA 92, 7686-7689 (1995). The first report of a small-molecule MEK inhibitor, PD098059. Findings with this compound have subsequently been reported in over 2,000 publications, documenting the central role of the MAPK pathway in a diverse array of physiological events, including tumour proliferation, differentiation, angiogenesis and survival.
10. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D.T. & Saltiel, A. R. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494 (1995).
11. Brondello, J. M., McKenzie, R. R., Sun, H., Tonks, N. K. & Pouyssegur, J. Constitutive MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene transcription and S-phase entry in fibroblasts. Oncogene 10, 1895-1904 (1995).
12. MAPK pathway. J. Biol. Chem. 271, 20608-20616 (1996).
13. kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl Acad. Sci. USA 95, 1091-1096 (1998).
14. Cook, S. J., Aziz, N. & McMahon, M. The repertoire of Fos and Jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol. Cell. Biol. 19, 330-341 (1999).
15. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185 (1995).
16. Raabe, T. & Rapp, U. R. Ras signaling: PP2A puts Ksr and Raf in the right place. Curr. Biol. 13, R635-R637 (2003).
17. Cip1. Mol. Cell. Biol. 17, 5588-5597 (1997).
18. Pumiglia, K. M. & Decker, S. J. Cell cycle arrest mediated by the MEK/migogen-activated protein kinase pathway. Proc. Natl Acad. Sci. USA 94, 448-452 (1997).
19. Zhang, B. H. et al. Serum- and glucocorticoid-inducible kinase SGK phosphorylate and negatively regulates B-Raf. J. Biol. Chem. 276, 31620-31626 (2001).
20. Guan, K. L. et al. Negative regulation of the serine/threonine kinase B-raf by Akt. J. Biol. Chem. 275, 27354-27359 (2000).
21. Murphy, L. O., MacKeigan, J. P. & Blenis, J. A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol. Cell. Biol. 24, 144-153 (2004).
22. Murphy, L. O., Smith, S., Chen, R. H., Fingar, D. C. & Blenis, J. Molecular interpretation of ERK signal duration by immediate early gene products. Nature Cell Biol. 4, 556-564 (2002).
23. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512 (1999).
24. cip1 expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 phase. J. Cell Biol. 146, 1255-1264 (1999).
25. mapk isoforms in the G1 phase and their inactivation at the G1/S transition. J. Cell Physiol. 163, 577-588 (1995).
26. Herrera, R. & Sebolt-Leopold, J. S. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol. Medicine 8, S27-S31 (2002).
27. Chen, J. et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc. Natl Acad. Sci. USA 98, 7783-7788 (2001).
28. Shimamura, A. et al. Rsk 1 mediates a MEK-MAP kinase cell survival signa. Curr. Biol. 10, 127-135 (2000).
29. Bonni, A. et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286, 1358-1362 (1999).
30. Baumann, B. et al. Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc. Natl Acad. Sci. USA 97, 4615-4620 (2000).
31. Murakami, M. S. & Morrison, D. K. Raf-1 without MEK? Sci. STKE 99, PE3O (2001).
32. Ballif, B. A. & Blenis, J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 12, 397-408 (2001).
33. Pages, G. et al. Defective thymocyte maturation in p44 MAP kinase (Erk1) knockout mice. Science 286, 1374-1377 (1999).
34. Giroux, S. et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 9, 369-376 (1999).
35. Howe, A. K., Aplin, A. E. & Juliano, R. L. Anchorage-dependent ERK signaling - mechanisms and consequences. Curr. Opin. Genet. Dev. 12, 30-35 (2002).
36. Wada, T. & Penninger, J. M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23, 2838-2849 (2004).
37. Platanias, L. C. MAP kinase signaling pathways and hematologic malignancies. Blood 101, 4667-4679 (2003).
38. Stanton, L. A., Underhill, T. M. & Beier, F. MAP kinases in chondrocyte differentiation. Dev. Biol. 263, 165-175 (2003).
39. Hofman, P. Molecular regulation of neutrophil apoptosis and potential targets for therapeutic strategy against the inflammatory process. Curr. Drug Targets. Inflamm. Allergy 3, 1-9 (2004).
40. Ji, R. R. Mitogen-activated protein kinases as potential targets for pain killers. Curr. Opin. Investig. Drugs 5, 71-75 (2004).
41. Sugden, P. H. Signalling pathways in cardiac myocyte hypertrophy. Ann. Med. 33, 611-622 (2001).
42. Barron, A. J., Finn, S. G. & Fuller, S. J. Chronic activation of extracellular-signal-regulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytes. Biochem. J. 371, 71-79 (2003).
43. Downward, J. Targeting Ras signaling pathways in cancer therapy. Nature Rev. Cancer 3, 11-22 (2003).
44. Sebti, S. M. & Der, C. J. Searching for the elusive targets of farnesyltransferase inhibitors. Nature Rev. Cancer 3, 945-951 (2003).
45. Zhu, K., Hamilton, A. D. & Sebti, S. M. Farnesyltransferase inhibitors as anticancer agents: current status. Curr. Opin. Invest. Drugs 4, 1428-1435 (2003).
46. End, D. W. et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61, 131-137 (2001).
47. van Cutsem, E. et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol. 21, A517 (2002).
48. Liu, A., Du, W., Liu, J. P., Jessell, T. M. & Prendergast, G. C. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol. 20, 6105-6113 (2000).
49. Katz, M. E. & McCormick, F. Signal transduction from multiple Ras effectors. Curr. Opin. Genet. Dev. 7, 75-79 (1997).
50. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002). Seminal discovery of somatic mutations of BRAF in human cancer. This report described the prevalence of BRAF mutations in melanoma and led to BRAF being viewed as a promising target for drug development for this patient population.
51. Satyamoorthy, K. et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63, 756-759 (2003).
52. Rajagopalan, H. et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934 (2002).
53. Yuen, S. T. et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 62, 6451-6455 (2002).
54. Singer, G. et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl Cancer Inst. 95, 484-486 (2003).
55. Cohen, Y. et al. BRAF mutation in papillary thyroid carcinoma. J. Natl Cancer Inst. 95, 625-627 (2003).
56. Kimura, E. T. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454-1457 (2003).
57. Karasarides, M. et al. B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298 (2004). Reports the use of RNA interference to demonstrate that BRAF depletion impairs ERK signalling and proliferation in melanoma cells, unlike ARAF and RAF1 depletion. These findings strengthened the argument for developing a BRAF-targeted therapeutic agent against melanoma.
58. Tuveson, D. A., Weber, B. L. & Herlyn, M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4, 95-98 (2003).
59. Bollag, G., Freeman, S., Lyons, J. F. & Post, L. E. Raf pathway inhibitors in oncology. Curr. Opin. Invest. Drugs 4, 1436-1441 (2003).
60. Lee, J. T. & McCubrey, J. A. BAY-43-9006 Bayer/Onyx. Curr. Opin. Invest. Drugs. 4, 757-763 (2003).
61. Hotte, S. J. & Hirte, H. W. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr. Pharm. Des. 8, 2249-2253 (2002).
62. DeGrendele, H. Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors. Clin. Colorectal Cancer 3, 16-18 (2003).
63. Verheul, H. M. & Pinedo, H. M. Vascular endothelial growth factor and its inhibitors. Drugs Today (Barc) 39 (Suppl. C), 81-93 (2003).
64. Hilger, R. A. et al. ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY 43-9006. Int. J. Clin. Pharmacol. Ther. 40, 567-568 (2002).
65. Chong, H., Vikis, H. G., Guan, K. L. Mechanisms of regulating the Raf kinase family. Cell Signal. 15, 463-469 (2003).
66. Mercer, K. E. & Pritchard, C. A. Raf proteins and cancer: B-Raf is identified as a mutational tartet. Biochim. Biophys. Acta 1653, 25-40 (2003).
67. Wan, P. T. C. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004). Describes the crystal structure of wild-type and oncogenic BRAF kinase domains. This important study provides insight into how BRAF is activated and how mutations in this protein lead to tumorigenesis.
68. Dibb, N. J., Dilworth, S. M. & Mol, C. D. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nature Rev. Cancer 4, 718-727 (2004).
69. Cowley, S., Paterson, H., Kemp, P. & Marshall, C. J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH3T3 cells. Cell 77, 841-852 (1994).
70. Mansour, S. J. et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970 (1994). Although MEK is not an oncogene, this study showed that constitutively activated MEK possesses transforming activity, providing the impetus for targeting the MAPK pathway in the development of molecular-targeted drugs.
71. Hoshino, R. et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822 (1999).
72. mapk by MAP kinase kinase. FEBS Lett. 306, 17-22 (1992).
73. Sebolt-Leopold, J. S. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr. Pharmaceutical Design 10, 1907-1914 (2004).
74. Favata, M. F. et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623-18632 (1998).
75. Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 81-816 (1999). The first report of a small-molecule MEK inhibitor having efficacy in tumour-bearing mice. Importantly, pharmacodynamic assays linked antitumour efficacy with suppression of the MAPK pathway.
76. Allen, L. F., Sebolt-Leopold, J. S. & Meyer, M. Cl-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30, 105-116 (2003).
77. Rinehart, J. et al. Multicenter phase 2 study of the oral MEK inhibitor, Cl-1040, in patients with advanced non-small-cell lung, breast, colon and pancreatic cancer. J. Clin. Oncol. 13 Oct 2004 (doi:10.1200/JCO.2004.01.185)
78. Ohren, J. et al. Structures of human MAP Kinase Kinase 1 (MEK1) and MEK2 reveal a novel mode of non-competitive kinase inhibition. Nature Struct. Biol. (in the press). Structural evidence that both MEK1 and MEK2 possess a unique inhibitor-binding pocket adjacent to the ATP-binding site. This explains the high degree of selectivity observed with MEK inhibitors in clinical development.
79. Bishop, A. C. A hot spot for protein kinase inhibitor sensitivity. Chem. Biol. 11, 587-591 (2004).
80. Tamborini, E. et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127, 294-299 (2004).
81. Yeung, K. et al. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol. Cell. Biol. 20, 3079-3085 (2000).
82. Wang, Y. et al. The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol. Cell. Biol. 22, 916-926 (2002).
83. Matheny, S. A. et al. Ras regulates assembly of mitogenic signaling complexes through the effector protein IMP. Nature 427, 256-260 (2004).
84. Farooq, A. & Zhou, M.-M. Structure and regulation of MARK phosphatases. Cell. Signalling 16, 769-779 (2004).
85. Shapiro, P. S. & Ahn, N. G. Feedback regulation of Raf-1 and mitogen-activated protein kinase (MAP) kinase kinases 1 and 2 by MAP kinase phosphatase-1 (MKP-1). J. Biol. Chem. 273, 1788-1793 (1998).
86. Guan, K. L. et al. Negative regulation of the serine/threonine kinase B-Raf by Akt. J. Biol. Chem. 275, 27354-27359 (2000).
87. Zhang, B. H. et al. Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf. J. Biol. Chem. 276, 31620-31626 (2001).
88. Sivaraman et al. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99, 1478-1483 (1997).
89. El-Ashry et al. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15, 423-435 (1997).
90. Coutts A. S. & Murphy, L. C. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res. 58, 4071-4074 (1998).
91. Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 276, 40888-40895 (2001).
92. Lee, S. H. et al. Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. APMIS 112, 233-238 (2004).
93. Wang, H. & Chakrabarty, S. Platelet-activating factor activates mitogen-activated protein kinases, inhibits proliferation, induces differentiation and suppresses the malignant phenotype of human colon carcinoma cells. Oncogene 22, 2186-2191 (2003).
94. Vial, E. & Marshall, C. J. Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci 116, 4957-4963 (2003).
95. Ishino, K. et al. Enhancement of anchorage-independent growth of human pancreatic carcinoma MlA PaCa-2 cells by signaling from protein kinase C to mitogen-activated protein kinase. Mol. Carcinog. 34, 180-186 (2002).
96. Tan, X. et al. Relationship between the expression of extracellular signal-regulated kinase 1/2 and the dissociation of pancreatic cancer cells: involvement of ERK 1/2 in the dissociation status of cancer cells. Int. J. Oncol. 24, 815-820 (2004).
97. Manzano, R. G. et al. CL 100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 21, 4435-4447 (2002).
98. Gioeli, D., Mandell, J. W., Petroni, G. R., Frierson, H. F. Jr & Weber, M. J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59, 279-284 (1999).
99. Bakin, R. E., Gioeli, D., Sikes, R. A., Bissonette, E. A. & Weber, M. J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63, 1981-1989 (2003).
100. Zayzafoon, M., Abdulkadir, S. A. & McDonald, J. M. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J. Biol. Chem. 279, 3662-3670 (2004).
101. Eisenmann, K. M., VanBrocklin, M. W., Staffend, N. A., Kitchen, S. M. & Koo, H. M. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res. 63, 8330-8337 (2003).
102. Jorgensen, K., Holm, R., Maelandsmo, G. M. & Florenes, V. A. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin. Cancer Res. 9, 5325-5331 (2003).
103. Calipel, A. et al. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J. Biol. Chem. 278, 42409-42418 (2003).
104. Vicent, S. et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br. J. Cancer 90, 1047-1052 (2004).
105. Mawrin, C. et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J. Oncol. 23, 641-648 (2003).
106. Meng, X. W. et al. Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor Cl-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J. Biol. Chem. 278, 47326-47339 (2003).
107. Milella, M., Kornblau, S. M. & Andreeff, M. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev. Clin. Exp. Hematol. 7, 160-190 (2003).
108. Lunghi, P. et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 17, 1783-1793 (2003).
109. Carter, C. et al. Anti-tumour efficacy of the orally active Raf kinase inhibitor BAY 43-9006 in human tumour xenograft models. Proc. Annu. Meet. Am. Assoc. Cancer Res. 42, A4954 (2001).
110. Wallace, E. et al. Preclinical development of ARRY-142886, a potent and selective MEK inhibitor. Proc. Annu. Meet. Am. Assoc. Cancer Res. 45, A3891 (2004).